NVCN.TO - Neovasc Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.78
-0.03 (-3.70%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close0.81
Open0.83
Bid0.79 x 0
Ask0.79 x 0
Day's Range0.77 - 0.83
52 Week Range0.77 - 2.88
Volume78,103
Avg. Volume75,032
Market Cap78.798M
Beta0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.44
  • CNW Group9 days ago

    Neovasc Reducer Featured in Live Case at ICI 2017

    VANCOUVER, Dec. 6, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case" broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel.  In the live case broadcast to the conference from the Soroka University Medical Center in Beersheba Israel, Drs. Koifman and Bazan successfully implanted a Reducer in the coronary sinus of a patient suffering from very poor quality of life due to refractory angina pectoris, chest discomfort felt with even minimal effort, despite previous bypass surgery and multiple stent implantations. The live Reducer case was broadcast following a scientific presentation describing current available clinical data supporting the use of the Reducer as a safe and effective therapy for patients with refractory angina pectoris.

  • PR Newswire9 days ago

    Neovasc Reducer Featured in Live Case at ICI 2017

    VANCOUVER, Dec. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case" broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel.  In the live case broadcast to the conference from the Soroka University Medical Center in Beersheba Israel, Drs. Koifman and Bazan successfully implanted a Reducer in the coronary sinus of a patient suffering from very poor quality of life due to refractory angina pectoris, chest discomfort felt with even minimal effort, despite previous bypass surgery and multiple stent implantations. The live Reducer case was broadcast following a scientific presentation describing current available clinical data supporting the use of the Reducer as a safe and effective therapy for patients with refractory angina pectoris.

  • CNW Group18 days ago

    Neovasc to Present at the Piper Jaffray 29th Annual Healthcare Conference

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 27, 2017 /CNW/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN) (TSX: NVC) today announced that Chris Clark , chief financial officer, ...

  • PR Newswire18 days ago

    Neovasc to Present at the Piper Jaffray 29th Annual Healthcare Conference

    VANCOUVER, Nov. 27, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced that Chris Clark, chief financial officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29th at 7:50 am ET at the Lotte New York Palace in New York City. A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe.

  • CNW Group28 days ago

    Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants

    VANCOUVER, Nov. 17, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the "Series A Units") and 19,066,780 Series B units (the "Series B Units" and together with the Series A Units, the "Units") of the Company, at a price of US$1.46 per Unit for gross proceeds of approximately US$37,487,497, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Neovasc (the "Offering"). Concurrent with the Offering, the Company completed a private placement for the sale of US$32,750,000 aggregate principal amount of senior secured convertible notes and Series E warrants of the Company for gross proceeds of US$27,837,500 (the "Concurrent Private Placement").

  • PR Newswire28 days ago

    Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants

    VANCOUVER, Nov. 17, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the "Series A Units") and 19,066,780 Series B units (the "Series B Units" and together with the Series A Units, the "Units") of the Company, at a price of US$1.46 per Unit for gross proceeds of approximately US$37,487,497, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Neovasc (the "Offering"). Concurrent with the Offering, the Company completed a private placement for the sale of US$32,750,000 aggregate principal amount of senior secured convertible notes and Series E warrants of the Company for gross proceeds of US$27,837,500 (the "Concurrent Private Placement").

  • CNW Grouplast month

    Neovasc Announces Results for the Third Quarter of 2017

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 14, 2017 /CNW/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ended September ...

  • PR Newswirelast month

    Neovasc Announces Results for the Third Quarter of 2017

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ...

  • CNW Grouplast month

    Neovasc to Host Third Quarter 2017 Conference Call

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 10, 2017 /CNW/ -  Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for ...

  • PR Newswirelast month

    Neovasc to Host Third Quarter 2017 Conference Call

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 10, 2017 /PRNewswire/ -  Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced that it will release its financial results ...

  • CNW Grouplast month

    Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 9, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 ...

  • PR Newswirelast month

    Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 9, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq: NVCN) today announced that it has priced an underwritten offering of 6,609,588 ...

  • Baystreetlast month

    Stocks in play: Neovasc Inc.

    Has received approval of the U.S. Food and Drug Administration to initiate the COSIRA-II IDE pivotal ...

  • PR Newswirelast month

    Neovasc Receives FDA Approval to Initiate Pivotal Reducer Trial

    VANCOUVER, Nov. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced that it has received approval of the U.S. Food and Drug Administration ("FDA") to initiate the COSIRA-II IDE pivotal clinical trial.  The trial's purpose will be to demonstrate the safety and effectiveness of the Company's novel Reducer system for treatment of patients with refractory angina. Once completed, the trial data is intended to support an application to the FDA for approval to begin marketing Reducer in the United States. "Since its commercial launch in Europe two years ago, Reducer has consistently provided relief of severe symptoms in patients suffering from refractory angina, resulting in significant improvements in their quality of life," commented Neovasc CEO, Alexei Marko.

  • CNW Grouplast month

    Neovasc Provides Litigation Update

    VANCOUVER, Nov. 3, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) reported today that the United States Court of Appeals for the Federal Circuit affirmed the judgment of the United States District Court for the District of Massachusetts in the case of CardiAQ Valve Tech., Inc. v. Neovasc Inc.  and denied the petition for panel rehearing and en banc rehearing filed by CardiAQ Valve Technologies, Inc. ("CardiAQ") and denied the petition for en banc rehearing filed by the Company.  The mandate of the court will issue on November 13, 2017. In summary, the appeals process is now exhausted.  The full judgment of approximately US$112 million, of which approximately US$70 million is already held in an escrow account, will now become due on November 13, 2017.  Neovasc will continue to evaluate all options available to the Company relating to the requirement to pay the damages and fund the remaining US$42 million not held in escrow, which exceeds the Company's current cash resources.